HIV-1 SUBTYPE B TAT GENE ACTIVITIES AND DISEASE PROGRESSION IN HIV-1 CRF01_AE INFECTION

被引:0
作者
Niyasom, Chaisit [1 ]
Horthongkham, Navin [1 ]
Sreephiang, Apichai [1 ]
Kantakamalakul, Wannee [1 ]
Louisirirotchanakul, Suda [1 ]
Chuenchitra, Thippawan [2 ]
Sutthent, Ruengpung [1 ]
机构
[1] Mahidol Univ, Fac Med, Dept Microbiol, Siriraj Hosp, Bangkok 10700, Thailand
[2] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSACTIVATOR GENE; PROTEIN; REPLICATION; EXPRESSION; RNA; TRANSCRIPTION; PROMOTER; VACCINES; STRAINS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
HIV-1 tat gene function and immunogenicity of HIV-1 Tat protein from 3 low (PS01, PS40, PS58) and 3 high (PS19, PS65, LP22) viral load infected, untreated and asymptomatic individuals from Thailand were compared. Levels of Tat-dependent chloramphenicol acetyltransferase (CAT) induced in HL3T1 cells with tat1 gene from HIV-1 isolates of high viral load group was significantly higher than those from low viral load group. HIV-1 subtype determination using env (C2-V4) gene demonstrated that 2/3 (PS01 and PS40) and 1/3 (PS58) from low viral load group were CRF01_AE and subtype B, while all 3 HIV-1 isolates from high viral load group were CRF01_AE. However, all 3 HIV-1 tat nucleotide sequences from low viral load group, which contained env CRF01_AE sequence, belonged to subtype B whereas all those from high viral load group contained CRF01_AE sequence. HIV Tat recombinant proteins from these groups were tested for immunogenicity in mice. All recombinant Tat proteins (except from PS58) were immunogenic in a dose-dependent manner, but with significantly differences of the immunogenicity levels between high and low viral load groups. These results indicated that HIV-1 subtype B tat gene activities might be associated with reduced disease progression of HIV-1 CRF01_AE infected individuals.
引用
收藏
页码:748 / 758
页数:11
相关论文
共 31 条
[1]   Recent advances in the development of HIV-1 Tat-based Vaccines [J].
Caputo, A ;
Gavioli, R ;
Ensoli, B .
CURRENT HIV RESEARCH, 2004, 2 (04) :357-376
[2]   THE TRANSACTIVATOR GENE OF THE HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-III IS REQUIRED FOR REPLICATION [J].
DAYTON, AI ;
SODROSKI, JG ;
ROSEN, CA ;
GOH, WC ;
HASELTINE, WA .
CELL, 1986, 44 (06) :941-947
[3]   EVOLUTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NEF AND LONG TERMINAL REPEAT SEQUENCES OVER 4 YEARS INVIVO AND INVITRO [J].
DELASSUS, S ;
CHEYNIER, R ;
WAINHOBSON, S .
JOURNAL OF VIROLOGY, 1991, 65 (01) :225-231
[4]   Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins [J].
Desfosses, Y ;
Solis, M ;
Sun, Q ;
Grandvaux, N ;
Van Lint, C ;
Burny, A ;
Gatignol, A ;
Wainberg, MA ;
Lin, RT ;
Hiscott, J .
JOURNAL OF VIROLOGY, 2005, 79 (14) :9180-9191
[5]   CONSTRUCTION OF A REPLICATION-COMPETENT MURINE RETROVIRUS VECTOR EXPRESSING THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT TRANSACTIVATOR PROTEIN [J].
DILLON, PJ ;
LENZ, J ;
ROSEN, CA .
JOURNAL OF VIROLOGY, 1991, 65 (08) :4490-4493
[6]  
Ensoli B, 2002, VIRUS RES, V82, P91
[7]   THE TRANSACTIVATOR GENE OF HTLV-III IS ESSENTIAL FOR VIRUS-REPLICATION [J].
FISHER, AG ;
FEINBERG, MB ;
JOSEPHS, SF ;
HARPER, ME ;
MARSELLE, LM ;
REYES, G ;
GONDA, MA ;
ALDOVINI, A ;
DEBOUK, C ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1986, 320 (6060) :367-371
[8]   EFFECT OF ANTIBODY TO HIV-1 TAT PROTEIN ON VIRAL REPLICATION IN-VITRO AND PROGRESSION OF HIV-1 DISEASE IN-VIVO [J].
FURLINI, MCRG ;
VIGNOLI, M ;
RAMAZZOTTI, E ;
RODERIGO, G ;
DEROSA, V ;
ZAULI, G ;
LOLLI, S ;
CAPITANI, S ;
LAPLACA, M .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 (04) :408-416
[9]   Tat is required for efficient HIV-1 reverse transcription [J].
Harrich, D ;
Ulich, C ;
GarciaMartinez, LF ;
Gaynor, RB .
EMBO JOURNAL, 1997, 16 (06) :1224-1235
[10]   Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains [J].
Huang, L ;
Bosch, I ;
Hofmann, W ;
Sodroski, J ;
Pardee, AB .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8952-8960